drugset / Trial / NCT06933524
Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of ATB-320 in patients with progressive or metastatic solid tumors
Timeline
- Start
- 2025-12-01
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATB-320 | Unknown | 1 mg/kg | Intravenous |
| Subject | ATB-320 | Unknown | 2 mg/kg | Intravenous |
| Subject | ATB-320 | Unknown | 4 mg/kg | Intravenous |
| Subject | ATB-320 | Unknown | 8 mg/kg | Intravenous |